Application 761312

Type
BLA
Sponsor
CITIUS PHARMS

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761312Lymphirdenileukin diftitox-cxdl351(a)Rx2026-06-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001LYMPHIRDENILEUKIN DIFTITOX-CXDLINJECTABLE;INJECTION300MCGNoNo

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 ยท 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
LYMPHIRDENILEUKIN DIFTITOX-CXDLCitius Pharmaceuticals, Inc.ac3613d7-4304-40e7-a3f5-adb8a8adca5d2025-01-23Boxed warning, Warnings, Adverse reactionsExact identifier
application number: BLA761312

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
82913ORIG 2025-07-23
79354ORIG 2024-08-09
79344ORIG 2024-08-08